Canada Pension Plan Investment Board Takes $673,000 Position in Omnicell, Inc. $OMCL

Canada Pension Plan Investment Board acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 16,200 shares of the company’s stock, valued at approximately $673,000.

Several other large investors have also made changes to their positions in OMCL. Dana Investment Advisors Inc. purchased a new stake in Omnicell during the fourth quarter valued at about $3,445,000. Bank of America Corp DE raised its holdings in shares of Omnicell by 31.3% in the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock worth $19,390,000 after purchasing an additional 138,537 shares during the period. Jackson Creek Investment Advisors LLC purchased a new position in shares of Omnicell in the 4th quarter worth about $2,022,000. BlackRock Inc. acquired a new position in shares of Omnicell in the 2nd quarter valued at about $313,044,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock valued at $81,791,000 after purchasing an additional 137,834 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Wells Fargo & Company decreased their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Zacks Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Trading Down 1.8%

Shares of OMCL opened at $34.51 on Wednesday. Omnicell, Inc. has a 12 month low of $29.06 and a 12 month high of $55.00. The stock’s 50-day moving average is $39.66 and its two-hundred day moving average is $39.30. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The stock has a market cap of $1.57 billion, a PE ratio of 41.08, a P/E/G ratio of 0.88 and a beta of 0.97.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities analysts forecast that Omnicell, Inc. will post 1.41 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.